Mäkelä Sanna M, Griffin Síle M, Reimari Jenni, Evans Kara C, Hibberd Ashley A, Yeung Nicolas, Ibarra Alvin, Junnila Jouni, Turunen Jari, Beboso Ronnie, Chhokar Balgit, Dinan Timothy G, Cryan John, Patterson Elaine
IFF Health & Biosciences, Kantvik, Finland.
IFF Health & Biosciences, Madison, USA.
Brain Behav Immun Health. 2023 Aug 1;32:100673. doi: 10.1016/j.bbih.2023.100673. eCollection 2023 Oct.
Lpc-37 (Lpc-37) has previously shown to reduce perceived stress in healthy adults. The ChillEx study investigated whether Lpc-37 reduces stress in a model of chronic examination stress in healthy students. One hundred ninety university students (18-40 y) were randomized to take 1.56 × 10 colony-forming units of Lpc-37 or placebo (1:1) each day for 10 weeks, in a triple-blind, parallel, multicenter clinical trial consisting of six visits: two screening visits, a baseline visit, and visits at 4, 8, and 10 weeks after baseline. The primary objective was to demonstrate that Lpc-37 reduces stress, as measured by the change in state anxiety from baseline to just before the first examination, after 8 weeks using the State Trait Anxiety Inventory (STAI-state). Secondary objectives aimed to demonstrate that Lpc-37 modulates psychological stress-induced symptoms and biomarkers related to mood and sleep. An exploratory analysis of fecal microbiota composition was also conducted. There was no difference between Lpc-37 and placebo groups in the change of STAI-state score (estimate 1.03; 95% confidence interval [CI]: -1.62, 3.67; p = 0.446). None of the secondary outcomes resulted in significant results when corrected for multiplicity, but exploratory results were notable. Results showed an improvement in sleep-disturbance scores (odds ratio 0.30; 95% CI: 0.11, 0.82; p = 0.020) and reduction in duration of sleep (odds ratio 3.52; 95% CI: 1.46, 8.54; p = 0.005) on the Pittsburgh Sleep Quality Index questionnaire after 8 weeks in the Lpc-37 group compared to placebo. A reduction in Bond Lader VAS-alertness was also demonstrated in the Lpc-37 group compared to placebo (estimate -3.97; 95% CI: -7.78, -0.15; p = 0.042) just prior to the examination. Analysis of fecal microbiota found no differences between study groups for alpha and beta diversity or microbiota abundance. Adverse events were similar between groups. Vital signs, safety-related laboratory measures, and gastrointestinal parameters were stable during the trial. In conclusion, probiotic Lpc-37 was safe but had no effect on stress, mood, or anxiety in healthy university students in this model of chronic academic stress. ClinicalTrials.gov: NCT04125810.
Lpc-37先前已被证明可减轻健康成年人的感知压力。ChillEx研究调查了Lpc-37在健康学生慢性考试压力模型中是否能减轻压力。在一项三盲、平行、多中心临床试验中,190名大学生(18 - 40岁)被随机分为两组,每天分别服用1.56×10个菌落形成单位的Lpc-37或安慰剂(1:1),持续10周,该试验包括六次访视:两次筛查访视、一次基线访视以及基线后4周、8周和10周的访视。主要目标是通过使用状态特质焦虑量表(STAI-状态),在8周后测量从基线到首次考试前状态焦虑的变化,来证明Lpc-37可减轻压力。次要目标旨在证明Lpc-37可调节心理压力诱发的与情绪和睡眠相关的症状及生物标志物。还对粪便微生物群组成进行了探索性分析。Lpc-37组和安慰剂组在STAI-状态评分变化方面无差异(估计值1.03;95%置信区间[CI]:-1.62,3.67;p = 0.446)。在对多重性进行校正后,所有次要结果均未得出显著结果,但探索性结果值得注意。结果显示,与安慰剂组相比,Lpc-37组在8周后匹兹堡睡眠质量指数问卷上的睡眠障碍评分有所改善(优势比0.30;95% CI:0.11,0.82;p = 0.020),睡眠时长缩短(优势比3.52;95% CI:1.46,8.54;p = 0.005)。与安慰剂组相比,Lpc-37组在考试前还表现出Bond Lader视觉模拟量表警觉性降低(估计值-3.97;95% CI:-7.78,-0.15;p = 0.042)。粪便微生物群分析发现,研究组之间在α和β多样性或微生物群丰度方面无差异。两组间不良事件相似。在试验期间,生命体征、与安全相关的实验室指标和胃肠道参数均稳定。总之,在这个慢性学业压力模型中,益生菌Lpc-37对健康大学生的压力、情绪或焦虑没有影响,但安全性良好。ClinicalTrials.gov:NCT04125810。